Rameda Announces Price Increase Approvals for All Its Top Products Corporate NewsBy Rameda AdminAugust 7, 2024
Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose Intolerance Corporate NewsBy Rameda AdminMay 28, 2024
Rameda Maintains its Impressive Momentum with the Launch of a New Type 2 Diabetes Product, Bolstering its Chronic Portfolio Corporate NewsBy adminNovember 28, 2023
Equinox Pharma Holding Limited (Equinox) increases stake in Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. Corporate NewsBy adminNovember 6, 2023
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. finalizes acquisition of a portfolio of 11 fast-growing cardiometabolic products Corporate NewsBy adminJune 1, 2023
